[go: up one dir, main page]

CO2017011969A2 - Derivados de imidazo[1,2-b][1,2,4]triazina como agentes antiparasitarios - Google Patents

Derivados de imidazo[1,2-b][1,2,4]triazina como agentes antiparasitarios

Info

Publication number
CO2017011969A2
CO2017011969A2 CONC2017/0011969A CO2017011969A CO2017011969A2 CO 2017011969 A2 CO2017011969 A2 CO 2017011969A2 CO 2017011969 A CO2017011969 A CO 2017011969A CO 2017011969 A2 CO2017011969 A2 CO 2017011969A2
Authority
CO
Colombia
Prior art keywords
imidazo
triazine derivatives
antiparasitic agents
compound
leishmaniasis
Prior art date
Application number
CONC2017/0011969A
Other languages
English (en)
Inventor
Timothy James Miles
Michael George Thomas
Stephen Brand
Elisabet Viayna Gaza
Ian Gilbert
Eun Jung Ko
Martin Maria Marco
Lars Henrik Sandberg
Original Assignee
Glaxosmithkline Ip Dev Ltd
The Univ Of Dundee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd, The Univ Of Dundee filed Critical Glaxosmithkline Ip Dev Ltd
Publication of CO2017011969A2 publication Critical patent/CO2017011969A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un compuesto de Formula (I), o una de sus sales, (I) composiciones que comprenden el compuesto, procedimientos para su preparación y su uso en terapia, por ejemplo, en el tratamiento de enfermedades parasitarias tales como enfermedad de Chagas, tripanosomiasis africana humana (HAT) y leishmaniasis, particularmente leishmaniasis visceral (VL).
CONC2017/0011969A 2015-05-29 2017-11-24 Derivados de imidazo[1,2-b][1,2,4]triazina como agentes antiparasitarios CO2017011969A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15382283 2015-05-29
PCT/EP2016/061887 WO2016193111A1 (en) 2015-05-29 2016-05-26 Imidazo[1,2-b][1,2,4]triazine derivatives as antiparasitic agents

Publications (1)

Publication Number Publication Date
CO2017011969A2 true CO2017011969A2 (es) 2018-02-09

Family

ID=53398015

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0011969A CO2017011969A2 (es) 2015-05-29 2017-11-24 Derivados de imidazo[1,2-b][1,2,4]triazina como agentes antiparasitarios

Country Status (14)

Country Link
US (1) US10065965B2 (es)
EP (1) EP3303336A1 (es)
JP (1) JP2018516265A (es)
CN (1) CN107922419A (es)
AR (1) AR104749A1 (es)
AU (1) AU2016269626B2 (es)
BR (1) BR112017025668A2 (es)
CA (1) CA2987329A1 (es)
CL (1) CL2017003025A1 (es)
CO (1) CO2017011969A2 (es)
CR (1) CR20170546A (es)
TW (1) TW201713661A (es)
UY (1) UY36688A (es)
WO (1) WO2016193111A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10399966B2 (en) 2016-01-21 2019-09-03 University Of Washington Compounds for treatment of trypanosomes and neurological pathogens and uses thereof
JOP20190278A1 (ar) * 2017-05-31 2019-11-28 Novartis Ag مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية
EA039324B1 (ru) * 2017-11-06 2022-01-13 Новартис Аг 5,6–конденсированные бициклические соединения и композиции для лечения паразитарных заболеваний
CN108129409B (zh) * 2018-01-22 2020-07-03 三金集团湖南三金制药有限责任公司 一种改进的合成拉莫三嗪的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010151799A2 (en) * 2009-06-26 2010-12-29 University Of Massachusetts Compounds for modulating rna binding proteins and uses therefor
WO2014151630A2 (en) 2013-03-15 2014-09-25 Irm Llc Compounds and compositions for the treatment of parasitic diseases
US9296754B2 (en) * 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
UY35400A (es) 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
TN2016000253A1 (en) * 2013-12-19 2017-10-06 Novartis Ag [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis.

Also Published As

Publication number Publication date
JP2018516265A (ja) 2018-06-21
WO2016193111A1 (en) 2016-12-08
CL2017003025A1 (es) 2018-03-16
AU2016269626A1 (en) 2017-12-14
AU2016269626B2 (en) 2019-05-30
AR104749A1 (es) 2017-08-09
CA2987329A1 (en) 2016-12-08
UY36688A (es) 2016-12-30
EP3303336A1 (en) 2018-04-11
US20180141949A1 (en) 2018-05-24
CR20170546A (es) 2018-04-02
BR112017025668A2 (pt) 2018-08-07
TW201713661A (zh) 2017-04-16
CN107922419A (zh) 2018-04-17
US10065965B2 (en) 2018-09-04

Similar Documents

Publication Publication Date Title
CR20160523A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CO2018003969A2 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona
CL2015002635A1 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CO2018004933A2 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
NI201800033A (es) Derivados de 8-[6-[3-(amino)propoxi]-3piridil]-1-isopropil-imidazo[4, 5-c]quinolin -2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer.
MX379530B (es) Compuestos agonistas del receptor muscarínico m4.
CU20170162A7 (es) Derivados de fenil-tieno(2,3-d)pirimidina-hidroxiácido útiles en el tratamiento del cáncer y enfermedades autoinmunes, método de preparación de los mismos y composiciones farmacéuticas que los contienen
MX2023000782A (es) 7-bencil-4-(2-metilbencilo)-2,4,6,7,8,9-hexahidroimidazo [1,2-a]pirido[3,4-e]pirimidin-5(1h)-ona, analogos y sales del mismo y su uso en terapia.
MX2016014308A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7.
MX2016015248A (es) Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.
UY38625A (es) Compuestos y su uso en el tratamiento del cáncer
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
DOP2016000308A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
MX2018004295A (es) Compuestos, composiciones farmáceuticas y métodos de uso de agonistas de ppar.
CL2016001421A1 (es) Derivados de [1,2,4] triazolo [1,5-a] pirimidina como inhibidores de proteasoma para el tratamiento de enfermedades parasitarias como la leishmaniasis.
CO2017011969A2 (es) Derivados de imidazo[1,2-b][1,2,4]triazina como agentes antiparasitarios
CY1124151T1 (el) Ενωσεις
DOP2017000018A (es) [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas